Promethera’s mission is to bring patients life-saving treatments to reduce the need for liver transplantation.
Latest news
Promethera Biosciences is proud to announce that our CEO John Tchelingerian has been acknowledged by Global Business Awards 2019 for his leadership at Promethera!
The Global Business Awards are dedicated to the recognition of businesses, business owners and notable business leaders who continue to grow and develop their company – to stay ahead of the competition.
Disease Focus
Promethera is pioneering the development of novel cell-based therapies for the treatment of a broad variety of liver diseases. The Company’s platform has the potential to deliver novel therapeutic options for inherited disorders including hemophilia as well as acquired chronic and acute liver diseases such as Acute-on-Chronic-Liver Failure (ACLF), fibrosis and Non-Alcoholic Steatohepatits (NASH).
Pipeline
Promethera’s most advanced cell-based therapy, HepaStem, is currently being evaluated in an open-label Phase 2a clinical trial to treat patients with Acute-on-Chronic-Liver Failure (ACLF). The program has the potential to target more prevalent chronic or progressive severe liver diseases such as Non-Alcoholic Steatohepatitis (NASH) and Fibrosis. Promethera has further strengthened its pipeline with complementary biologics, including the anti-TNF-R1 antibody Atrosimab.
International Presence
Promethera Biosciences is headquartered in Belgium's Walloon region, which is internationally known for excellence in cell therapy research. From here, the company has begun early on to establish a global footprint with a US subsidiary in Durham, North Carolina, a biologics unit in Basel, Switzerland and a Japanese branch office in Tokyo. Each site serves a specific function within the Promethera Group structure.
